News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Under the brand name Kisqali, ribociclib has been approved in the US as a first line treatment for certain breast cancer patients, meaning Pfizer’s big-selling rival faces competition for the ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology Kidney Week 2024 showing that patients with C3 glomerulopathy treated with oral ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...

Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

"The Phase III NATALEE trial demonstrated a noteworthy 25.1% reduction in the risk of recurrence among patients with HR+/HER2- stage II and III early breast cancer receiving adjuvant Kisqali ...

EAST HANOVER, N.J., Oct. 24, 2024 /PRNewswire/ -- This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for breast cancer were updated to recommend ribociclib (Kisqali ®) ...